Sevohale (known as Sevocalm) (sevoflurane) – Summary of product characteristics - QN01AB08
Updated on site: 09-Feb-2018
|Ime zdravila:||Sevohale (known as Sevocalm)|
|Proizvajalec:||Chanelle Pharmaceuticals Manufacturing Limited|
1.NAME OF THE VETERINARY MEDICINAL PRODUCT
Sevohale 100% v/v Inhalation vapour, liquid for dogs.
2.QUALITATIVE AND QUANTITATIVE COMPOSITION
For the full list of excipients, see section 6.1.
Inhalation vapour, liquid.
Clear, colourless liquid.
4.2Indications for use, specifying the target species
For the induction and maintenance of anaesthesia.
Do not use in dogs with known hypersensitivity to sevoflurane or other halogenated anaesthetic agents.
Do not use in pregnant and lactating bitches (see section 4.7).
Do not use in dogs with a known or suspected genetic susceptibility to malignant hyperthermia. Do not use in dogs less than 12 weeks of age.
4.4Special warnings for each target species
4.5Special precautions for use
Special precautions for use in animals
Halogenated volatile anaesthetics can react with dry carbon dioxide (CO2) absorbents to produce carbon monoxide (CO) that may result in elevated levels of carboxyhaemoglobin in some dogs. In order to minimise this reaction in rebreathing anaesthetic circuits, Sevohale should not be passed through soda lime or barium hydroxide that has been allowed to dry out.
The exothermic reaction that occurs between inhalation agents (including sevoflurane) and CO2 absorbents is increased when the CO2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO2 absorbent canisters. Rare cases of excessive heat production, smoke and/or fire in the anaesthetic machine have been reported during the use of a desiccated CO2 absorbent and sevoflurane. An unusual decrease in the expected depth of anaesthesia compared to the vaporiser setting may indicate excessive heating of the CO2 absorbent canister.
If it is suspected that the CO2 absorbent may be desiccated, it must be replaced. The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO2 absorbents should be replaced routinely regardless of the state of the colour indicator.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure. Due to sevoflurane's low solubility in blood, these haemodynamic changes may occur more rapidly than with other volatile anaesthetics. Arterial blood pressure should be monitored at frequent intervals during sevoflurane anaesthesia. Facilities for artificial ventilation, oxygen enrichment and circulatory resuscitation should be immediately available. Excessive decreases in blood pressure or respiratory depression may be related to the depth of anaesthesia and may be corrected by decreasing the inspired concentration of sevoflurane. The low solubility of sevoflurane also facilitates rapid elimination by the lungs. The nephrotoxic potential of certain NSAIDs, when used in the perioperative period, may be exacerbated by hypotensive episodes during sevoflurane anaesthesia. In order to maintain renal blood flow, prolonged episodes of hypotension (mean arterial pressure below 60 mmHg) should be avoided in dogs during sevoflurane anaesthesia.
If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag. Appropriate treatment should readily be instituted.
Compromised or debilitated dogs
Doses of sevoflurane may need adjustment for geriatric or debilitated dogs. Doses required for maintenance anaesthesia may need to be reduced by approximately 0.5% in geriatric dogs (i.e. 2.8% to 3.1% in premedicated geriatric dogs and 3.2 to 3.3% in unpremedicated geriatric dogs). Limited clinical experience in administering sevoflurane to dogs with renal, hepatic and cardiovascular insufficiency suggests that sevoflurane may be safely used in these conditions. However, it is recommended that such animals be monitored carefully during sevoflurane anaesthesia.
Sevoflurane may cause a small increase in intracranial pressure (ICP) under conditions of normocapnia. In dogs with head injuries or other conditions placing them at risk from increased ICP, it is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of preventing changes in ICP.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In order to minimise exposure to sevoflurane vapour, the following recommendations are made:
•Use a cuffed endotracheal tube when possible for the administration of Sevohale during maintenance anaesthesia.
•Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia.
•Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour.
•All scavenging/extraction systems must be adequately maintained.
•Care should be taken when dispensing Sevohale, with immediate removal of any spillage.
•Do not inhale the vapour directly.
•Avoid contact by mouth.
•Halogenated anaesthetic agents may induce liver damage. This is an idiosyncratic response very occasionally seen after repeated exposure.
•From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment.
Direct exposure to eyes may result in mild irritation. If eye exposure occurs, the eye should be flushed with plenty of water for 15 minutes. Medical attention should be sought if irritation persists.
In case of accidental contact with the skin, wash the affected area with abundant water.
Symptoms of human overexposure (inhalation) to sevoflurane vapour include respiratory depression, hypotension, bradycardia, shivering, nausea and headache. If these symptoms occur, the individual should be removed from the source of exposure and medical attention sought.
Advice to doctors: Maintain a patent airway and give symptomatic and supportive treatment.
4.6Adverse reactions (frequency and seriousness)
The most frequently reported adverse reactions associated with Sevohale administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is reversible with anticholinergics.
Infrequent adverse reactions include paddling, retching, salivation, cyanosis, premature ventricular contractions and excessive cardiopulmonary depression.
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Hypotension during sevoflurane anaesthesia may result in decreased renal blood flow.
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.
The frequency of adverse reactions is defined using the following convention:
-very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-common (more than 1 but less than 10 animals in 100 animals treated)
-uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-rare (more than 1 but less than 10 animals in 10,000 animals treated)
-very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
4.7Use during pregnancy, lactation or lay
Do not use during pregnancy and lactation because the safety of the veterinary medicinal product has
not been established during pregnancy and lactation. However, there is limited clinical experience of the use of sevoflurane, after propofol induction, in bitches undergoing caesarean section, without any ill effects being detected in either the bitch or the puppies. Use only according to the risk/benefit assessment of the responsible veterinarian.
4.8Interaction with other medicinal products and other forms of interaction
Sevoflurane administration is compatible with the intravenous barbiturates and propofol. The concurrent administration of thiopental, however, may slightly increase sensitivity to adrenaline induced cardiac arrhythmias.
Benzodiazepines and Opioids:
Sevoflurane administration is compatible with benzodiazepines and opioids commonly used in veterinary practice. In common with other inhalational anaesthetics, the MAC of sevoflurane is reduced by the concurrent administration of benzodiazepines and opioids.
Sevoflurane is compatible with phenothiazines and
Studies using sevoflurane anaesthetic protocols that included atropine or glycopyrrolate as premedicants showed these anticholinergics to be compatible with sevoflurane in dogs.
In a laboratory study, the use of an acepromazine/oxymorphone/thiopental/sevoflurane anaesthetic regimen resulted in prolonged recoveries in all the dogs treated, compared to recoveries in dogs anaesthetised with sevoflurane alone.
The use of sevoflurane with nondepolarising muscle relaxants has not been evaluated in dogs. However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
4.9Amounts to be administered and administration route
Sevohale should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. Sevohale contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way. The administration of sevoflurane must be individualised based on the dog's response.
The necessity for and choice of premedication is left to the discretion of the veterinarian. Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.
Induction of anaesthesia:
For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog. These concentrations can be expected to produce surgical anaesthesia within 3 to 14 minutes and may be set initially, or may be achieved gradually over the course of 1 to 2 minutes. The use of premedicants does not affect the concentration
of sevoflurane required for induction.
Maintenance of anaesthesia:
Sevoflurane may be used for maintenance anaesthesia following mask induction with sevoflurane or following induction with injectable agents. The concentration of sevoflurane necessary to maintain anaesthesia is less than that required for induction.
Surgical levels of anaesthesia in the healthy dog may be maintained with inhaled concentrations of 3.3 to 3.6% in the presence of premedication. In the absence of premedication, inhaled concentrations of sevoflurane in the range 3.7 to 3.8% will provide surgical levels of anaesthesia in the healthy dog.
The presence of surgical stimulation may require an increase in the concentration of sevoflurane.
The use of injectable induction agents without premedication has little effect on the concentrations of sevoflurane required for maintenance.
Anaesthetic regimens that include opioid,
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Sevohale overdose may result in profound respiratory depression. Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/or assisted ventilation.
In cases of severe cardiopulmonary depression, administration of sevoflurane should be discontinued, the existence of a patent airway ensured, and assisted or controlled ventilation with pure oxygen initiated. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.
Due to sevoflurane's low solubility in blood, increasing the concentration may result in rapid haemodynamic changes
4.11 Withdrawal period(s)
Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code: QN 01AB08
Sevoflurane is an inhalational anaesthetic agent, having a light odour, for induction and maintenance of general anaesthesia. The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36%. Multiples of MAC are used as a guide for surgical levels of anaesthesia, which are typically 1.3 to 1.5 times the MAC value.
Sevoflurane produces unconsciousness by its action on the central nervous system. Sevoflurane produces only modest increases in cerebral blood flow and metabolic rate, and has little or no ability to potentiate seizures. Sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if hypocapnia is induced by hyperventilation.
Sevoflurane has a variable effect on heart rate, which tends to increase from baseline at low MAC and fall back with increasing MAC. Sevoflurane causes systemic vasodilation and produces dose dependent decreases in mean arterial pressure, total peripheral resistance, cardiac output and possibly the strength of myocardial contraction and speed of myocardial relaxation.
Sevoflurane has a depressive effect on respiration characterised by a fall in ventilation frequency. Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs.
Concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow. Hepatic oxygen delivery and consumption were not significantly altered at concentrations up to 2.0 MAC.
Sevoflurane administration adversely affects the autoregulation of renal blood flow in dogs. As a result, renal blood flow falls in a linear fashion with increasing hypotension in sevoflurane anaesthetised dogs. Nevertheless, renal oxygen consumption, and hence renal function, are preserved at mean arterial pressures above 40 mmHg.
A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30 °C is 0.63 to 0.69). During sevoflurane induction, there is a rapid increase in alveolar concentration towards the inspired concentration, with the ratio of inspired to
Sevoflurane is metabolised to a limited extent in the dog (1 to 5%). The principle metabolites are hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2. Fluoride ion concentrations are influenced by the duration of anaesthesia and the concentration of sevoflurane. Once formed, HFIP is rapidly conjugated with glucuronic acid and eliminated as a urinary metabolite. No other metabolic pathways for sevoflurane have been identified. In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/l have been observed after 3 hours of anaesthesia. Serum fluoride fell quickly after anaesthesia ended and had returned to baseline by 24 hours
The elimination of sevoflurane is biphasic in nature, with an initial rapid phase and a second, slower phase. Parent compound (the dominant fraction) is eliminated via the lungs. The
6.1List of excipients
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
6.4.Special precautions for storage
Do not store above 25 °C.
Do not refrigerate.
Keep the bottle tightly closed.
6.5Nature and composition of immediate packaging
250 ml Type III amber glass bottle with a yellow collar on the neck, sealed with a
Cardboard box containing either 1 or 6 bottles.
Not all pack sizes may be marketed.
6.6Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7.MARKETING AUTHORISATION HOLDER
Chanelle Pharmaceuticals Manufacturing Ltd.,
8.MARKETING AUTHORISATION NUMBER(S)
9.DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 21/06/2016
10.DATE OF REVISION OF THE TEXT
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/ .
PROHIBITION OF SALE, SUPPLY AND/OR USE